To further investigate the direct effects of HDAC6 inhibition on CLL B cell engagement with T cells, the patient-derived cell line, OSU-CLL, was utilized for in vitro assays. This evidence concerns the gene HDAC6 and B-cell chronic lymphocytic leukemia.